Core Insights - Applied Optoelectronics, Inc. (AOI) reported strong financial results for Q2 2025, with significant year-over-year revenue growth and gross margin expansion despite a net loss attributed to increased operating expenses [2][6]. Financial Performance - GAAP revenue for Q2 2025 was $103.0 million, a substantial increase from $43.3 million in Q2 2024 and slightly up from $99.9 million in Q1 2025 [6]. - GAAP gross margin was 30.3%, compared to 22.1% in Q2 2024 and 30.6% in Q1 2025 [6]. - The company reported a GAAP net loss of $9.1 million, or $0.16 per share, an improvement from a net loss of $26.1 million, or $0.66 per share in Q2 2024 [6]. Business Segments - The datacenter business showed steady growth, while the CATV business continued to experience strong demand [2]. - Revenue from the CATV segment was $56.0 million in Q2 2025, up from $5.8 million in Q2 2024, and the datacenter segment generated $44.8 million, compared to $34.4 million in the same period last year [18]. Strategic Initiatives - AOI is investing in R&D and SG&A to support new customer qualification efforts for advanced transceivers, which are expected to yield higher customer engagement and revenue opportunities [2]. - The company anticipates producing over 100,000 units of 800G transceivers per month by the end of 2025, with 40% of production occurring in the US [2]. Future Outlook - For Q3 2025, AOI expects revenue in the range of $115 million to $127 million and a non-GAAP gross margin between 29.5% and 31.0% [7]. - The company projects a non-GAAP net loss between $5.9 million and $2.0 million, translating to a loss per share of $0.10 to $0.03 [7].

Company Overview - Century Aluminum Company (NASDAQ:CENX) plans to restart over 50,000MT of idled production at its Mt. Holly, SC smelter with an investment of approximately $50 million [1] - The company is the largest producer of primary aluminum in the United States and operates production facilities in Iceland, the Netherlands, and Jamaica [5] Production and Economic Impact - The restart will create over 100 new jobs and boost U.S. domestic aluminum production by almost 10 percent [1] - The Mt. Holly smelter, when operating at full capacity, has an economic impact of over $890 million annually in South Carolina, with an average wage of $100,000 for jobs directly supported by Century Aluminum [3] Government and Regulatory Support - The restart is facilitated by President Trump's application of Section 232 tariffs, which recently increased tariffs on aluminum imports to 50% [2] - The South Carolina Public Service Authority (Santee Cooper) has cooperated with Century Aluminum to extend the current power supply contract through 2031, which is essential for the restart [4]

Core Insights - CytomX Therapeutics announced positive interim data from the ongoing Phase 1 study of CX-2051, an EpCAM Antibody Drug Conjugate, in patients with advanced colorectal cancer (CRC) [1][6] - The company completed a $100 million underwritten offering of common stock, with net proceeds of $93.4 million, enhancing its financial position to support ongoing and future clinical trials [6][8] - The anticipated data update for CX-2051 is expected in Q1 2026, with a Phase 2 study initiation planned for the first half of 2026 [1][3] Pipeline Program Updates - CX-2051 is currently undergoing dose expansions at 7.2 mg/kg, 8.6 mg/kg, and 10 mg/kg doses, administered every three weeks, with approximately 70 patients involved in the Phase 1 study [6] - CX-801, a masked interferon alpha-2b, is in Phase 1 dose escalation, with preliminary data expected in Q4 2025 [6] - Combination studies for CX-2051 in earlier lines of CRC therapy are being planned for 2026 [6] Financial Performance - Total revenue for Q2 2025 was $18.7 million, a decrease from $25.1 million in Q2 2024, primarily due to the completion of performance obligations in collaborations and reduced activities with Moderna [8][10] - Total operating expenses decreased to $19.9 million in Q2 2025 from $33.6 million in Q2 2024, reflecting a reduction in research and development expenses [9][10] - The company ended Q2 2025 with $158.1 million in cash, cash equivalents, and investments, compared to $79.9 million at the end of Q1 2025, providing a cash runway until Q2 2027 [7][8] Research Collaborations - CytomX has established strategic collaborations with major oncology leaders, including Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna, to advance its research and development efforts [12][14]

Core Insights - Altus Group Limited reported steady recurring revenue growth and margin expansion in Q2 2025, driven by significant growth in recurring new bookings and the launch of ARGUS Intelligence [2][6][10] - The company executed a share buyback of over $100 million, reflecting confidence in continued growth and profitability [2][5] Financial Performance - Revenue for Q2 2025 was C$131.5 million, a slight decrease of 0.8% compared to Q2 2024 [2] - Recurring revenue increased by 3.7% to C$100.8 million [2] - Profit from continuing operations was C$9.3 million, a significant improvement of 207.4% from a loss of C$8.6 million in Q2 2024 [2] - Adjusted EBITDA rose by 55.7% to C$28.5 million, with an adjusted EBITDA margin of 21.7%, up 790 basis points [2][6] - Free cash flow decreased by 30.5% to C$26.1 million [2] Business Outlook - The company revised its 2025 business outlook, projecting 3-6% total Analytics revenue growth and 5-7% recurring revenue growth for Q3 2025 [6][8] - Adjusted EBITDA margin expansion is expected to be 250-350 basis points [6] - The outlook reflects ongoing interest rate volatility and global trade uncertainty [8] Segment Performance - Analytics segment is expected to see consistency and growth in the number of assets on the Valuation Management Solutions platform [8] - Appraisals and Development Advisory is projected to have flat to low single-digit revenue growth [6][8] - Advisory segment anticipates 2-4% revenue growth [6][8] Cash Flow and Capital Management - Net cash provided by operating activities was C$27.8 million, down 30.3% from Q2 2024 [2] - The company’s funded debt to EBITDA ratio improved to 1.26 from 2.11 [2]

Core Points - Apyx Medical Corporation granted a nonstatutory stock option to John Featherstone, Vice President of North American Sales, for 100,000 shares as an inducement for employment [1][2] - The stock option has an exercise price of $1.85, which is the closing price of Apyx Medical's common stock on the grant date [2] - The stock option vests over a four-year period, with 25% vesting on the first anniversary and the remainder vesting annually, contingent on continued employment [2] Company Overview - Apyx Medical Corporation specializes in advanced energy technology, focusing on innovative products such as the Helium Plasma Platform Technology, marketed as Renuvion and AYON Body Contouring System in the cosmetic surgery market, and J-Plasma in the hospital surgical market [3] - Renuvion and J-Plasma provide surgeons with the ability to deliver controlled heat to tissue, supported by over 90 clinical documents [3] - The company also engages in OEM agreements with other medical device manufacturers, leveraging its expertise in unique waveforms [3]

Core Viewpoint - Biodesix, Inc. reported strong financial results for Q2 2025, with a revenue increase of 12% year-over-year, reaching $20.0 million, and reaffirmed its full-year revenue guidance of $80-85 million [1][6]. Financial Performance - Q2 2025 revenue was $20.0 million, a 12% increase compared to Q2 2024 [1][4]. - Gross profit margin for Q2 2025 was 80%, reflecting a 150-basis point improvement from the previous year [1][11]. - Development Services revenue grew by 53% year-over-year, reaching $2.1 million [5][20]. - Lung Diagnostic Testing revenue was $17.9 million, an 8% increase from the prior year, driven by an increase in total tests delivered [5][20]. - Adjusted EBITDA loss for Q2 2025 was $7.2 million, a 29% increase in loss compared to the same period last year [11][22]. Business Highlights - The sales team expanded to an average of 74 representatives, a 21% increase from the previous year [5]. - Primary care ordering of lung diagnostic tests increased over 100% compared to pre-pilot program levels in 2024 [5]. - The company achieved an all-time high in development services business dollars under contract, totaling $12.5 million, up 54% year-over-year [5]. - Digital ordering initiatives saw a 63% increase over the prior year [5]. - The company reached patient enrollment requirements for its ALTITUDE trial in July 2025 [5]. Future Outlook - The company is positioned to achieve Adjusted EBITDA positivity in Q4 2025, supported by sales team expansion and operational effectiveness [2]. - Biodesix maintains confidence in achieving its full-year revenue guidance of $80-85 million, indicating a focus on sustainable long-term growth [2][6].

Core Viewpoint - SharpLink Gaming, Inc. is set to host a conference call on August 15, 2025, to discuss its financial and operating results for the periods ending June 30, 2025, highlighting its position as a major holder of Ether and advocate for Ethereum adoption [1][4]. Group 1: Conference Call Details - The conference call will begin at 8:30 a.m. Eastern Time and will include a question-and-answer session [2]. - Participants can access the call via a "call me" option for instant telephone access, available 15 minutes before the start time [2]. - A telephonic replay will be available approximately three hours after the call concludes until August 29, 2025 [2]. Group 2: Company Overview - SharpLink Gaming, Inc. is headquartered in Minneapolis, Minnesota, and is one of the largest publicly traded companies adopting Ether as its primary treasury reserve asset [4]. - The company aims to align itself with the future of digital capital, providing investors with direct exposure to Ethereum, the leading smart-contract platform [4]. - SharpLink is focused on innovating the online gaming industry by developing scalable, secure, and transparent solutions [5].

CANTON, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Results Summary: Net product revenue of $100.8 million for the second quarter of 2025, a decrease of $29.5 million compa ...

– Announced strategic research collaboration with Chugai for two undisclosed molecules – – Presented preclinical data demonstrating bioequivalence of novel, bispecific GLP-1/GLP-2 receptor agonist delivered orally via RaniPill (RT-114) compared to subcutaneous delivery at ENDO 2025 – – Phase 1 study for RT-114 for the treatment of obesity expected to initiate in the second half of 2025 – – Announced a warrant inducement transaction with an existing investor with gross proceeds of $4.3 million – – Announced ...

NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Resolute Holdings Management, Inc. (“Resolute Holdings”) (Nasdaq: RHLD), an operating management company responsible for providing management services to CompoSecure Holdings, L.L.C. (“CompoSecure Holdings”), a wholly owned subsidiary of CompoSecure, Inc. (“CompoSecure”) (Nasdaq: CMPO), today reported financial results for its fiscal second quarter ending June 30, 2025. Resolute Holdings reported second quarter earnings per share attributable to common stockholder ...